

Reference:	FOI.17686.25
Subject:	Diffuse Large B Cell Lymphoma (DLBCL)
Date of Request:	2 July 2025

Requested:

1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?
2. Of these patients, how many commenced treatment at your trust within the last 6 months?
3. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
 - R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
 - R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
 - Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
 - Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)
 - R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)
 - R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)
 - R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)
 - (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)
 - R-GemOX (rituximab, gemcitabine and oxaliplatin)
 - Axicabtagene ciloleucel
 - Tisagenlecleucel
 - Epcoritamab
 - Loncastuximab tesirine
 - Glofitamab
 - Any other SACT
 - Stem cell transplant or bone marrow transplant (autologous or allogeneic)
4. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):
 - Axicabtagene ciloleucel (Yescarta)
 - Tisagenlecleucel
 - Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
 - R-GemOX (rituximab, gemcitabine and oxaliplatin)
 - Stem cell transplant or bone marrow transplant (autologous or allogeneic)
 - Any other treatments
5. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)?

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested for question 1 and 2, as it is estimated that the cost of answering your request would exceed the “appropriate limit” as stated in the Freedom of Information Act 2000 (Appropriate Limit and Fees) Regulations 2004. The “appropriate limit” represents the estimated cost of one person spending 18 hours (or 2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

The Welsh Clinical Portal (WCP) houses this information; however, it is not yet fully up to date for the period requested. Therefore, the UHB would need to undertake a manual trawl of the medical records of patients that have been diagnosed with and have commenced treatment for DLBCL to identify the relevant information.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under Section 16 of the FoIA, the UHB has a duty to provide advice and assistance. Therefore, the UHB provides the accessible information it holds below.

For question 5 and where the figures in the tables below have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients, due to the low number of cases (5 or less), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

Additionally, the UHB regrets to inform you that it does not hold the information requested for the following treatments: Axicabtagene ciloleucel, Tisagenlecleucel or Stem cell/bone marrow transplant. The UHB’s patients that require these treatments are seen, treated and managed within Cardiff and Vale University Health Board (C&VUHB). Therefore, we recommend that you redirect this part of your request to the Freedom of Information Team (Fol) at C&VUHB, who may be able to help you further. C&VUHB’s Fol team are contactable by email, at: FOI.Requests@wales.nhs.uk

- 1. & 2 – Section 12 exemption applied.

- 3. The UHB provides within the table below, the number of DLBCL patients that have received the treatments listed, as recorded on the ChemoCare system, during the period 1 January to 30 June 2025.

Medication	Number
R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)	9
R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)	*
Pola-BR (polatuzumab vedotin with rituximab and bendamustine)	0

Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)	10
R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)	0
R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)	0
R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)	0
(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)	0
R-GemOX (rituximab, gemcitabine and oxaliplatin)	0
Axicabtagene ciloleucel	**not held
Tisagenlecleucel	**not held
Epcoritamab	0
Loncastuximab tesirine	0
Glofitamab	0
Any other SACT	*
Stem cell transplant or bone marrow transplant (autologous or allogeneic)	**not held

4. The UHB provides within the table below, the number of DLBCL patients that have received the 2nd line treatments listed, as recorded on the ChemoCare system, during the period 1 January to 30 June 2025.

Medication	Number
Axicabtagene ciloleucel (Yescarta)	**not held
Tisagenlecleucel	**not held
Pola-BR (polatuzumab vedotin with rituximab and bendamustine)	0
R-GemOX (rituximab, gemcitabine and oxaliplatin)	0
Stem cell transplant or bone marrow transplant (autologous or allogeneic)	**not held
Any other treatments	0

5. Section 40 exemption applied.